Exchange & Returns Information
Review Details
(0)
| Generic For | PARAPLAIN |
|---|---|
| Active Ingredient | CARBOPLATIN |
| Strength | 450MG |
| Manufacturer | CIPLA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 39.90 | $ 39.90 |
$ 33.92
Apply ZARVY26 (-15%)
You save $ 5.99
|
||
| 2 BOXES - 2 VIALS | $ 42.95 | $ 85.90 |
$ 73.02
Apply ZARVY26 (-15%)
You save $ 12.89
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 43.63 | $ 130.90 |
$ 111.27
Apply ZARVY26 (-15%)
You save $ 19.64
|
Reference information will be available soon.
Cytocarb 450 is an intravenous formulation of carboplatin, a platinum-based chemotherapeutic agent used to treat various solid tumors. It exerts its cytotoxic effect by forming DNA intra-strand and inter-strand crosslinks, which inhibit DNA replication and transcription, ultimately inducing apoptosis. Compared to cisplatin, carboplatin has a more favorable toxicity profile, particularly in terms of nephrotoxicity and emetogenicity, making it a preferred alternative in elderly or renally compromised patients. It is commonly employed in combination regimens for ovarian cancer, lung cancers, and triple-negative breast cancer
AntiCancer Drugs > Ovarian Cancer
Used in both first-line and recurrent settings for platinum-sensitive ovarian carcinoma. Often combined with paclitaxel in the TC regimen, carboplatin plays a central role in primary and salvage chemotherapy strategies.
Non-Small Cell Lung Cancer (NSCLC)
Employed as part of platinum-doublet regimens alongside paclitaxel, gemcitabine, or pemetrexed. Preferred in patients who are ineligible for cisplatin due to comorbidities or renal impairment.
Small Cell Lung Cancer (SCLC)
Used in combination with etoposide in EP regimens, providing high response rates in patients with extensive-stage SCLC.
Triple-Negative Breast Cancer (TNBC)
Incorporated into combination chemotherapy regimens for its ability to induce DNA damage-mediated cytotoxicity in aggressive tumor subtypes.
Head & Neck, Endometrial, Esophageal, Testicular, and Bladder Cancers
Used as an alternative to cisplatin-based regimens or as part of customized combination therapies, particularly in patients at higher risk of cisplatin-related toxicity.
Platinum compound that alkylates DNA, forming covalent inter- and intra-strand crosslinks
Inhibits DNA synthesis and repair mechanisms
Induces apoptosis in rapidly dividing tumor cells
Exhibits reduced nephrotoxicity and ototoxicity compared to cisplatin
Ovarian Cancer (Single Agent)
→ 360 mg/m² IV infusion on Day 1 every 4 weeks
→ Re-treatment requires ANC ≥ 2000/mm³ and platelets ≥ 100,000/mm³
→ Alternatively, calculate dose using Calvert formula:
Total Dose (mg) = Target AUC × (GFR + 25)
→ Common AUC range: 4–6 mg·min/mL for previously treated patients
Ovarian Cancer (Combination with Cyclophosphamide)
→ Carboplatin: 300 mg/m² IV on Day 1 every 4 weeks × 6 cycles
→ Cyclophosphamide: 600 mg/m² IV on Day 1 every 4 weeks × 6 cycles
→ Hematologic thresholds must be met before each cycle
Administration Notes:
→ Administer via IV infusion over a minimum of 15 minutes
→ Hydration protocols generally not required
→ Dose adjustment may be needed in renal dysfunction
→ Cap GFR when using IDMS creatinine method if appropriate
Uses:
→ First-line and relapsed ovarian cancer
→ Combination chemotherapy for NSCLC and SCLC
→ Part of regimens in TNBC and other solid tumors
→ Preferred platinum agent in patients at risk of cisplatin toxicity
Store below 25°C
Do not freeze
Keep in original vial and protect from light
Shake well before use
Use immediately after dilution
Myelosuppression (especially thrombocytopenia, neutropenia)
Nausea and vomiting (less severe than cisplatin)
Anemia, fatigue
Renal function changes (rare compared to cisplatin)
Hypersensitivity reactions (especially after multiple cycles)
Ototoxicity (less common but possible)
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
